PORTOLA VALLEY, Calif., May 4, 2015 /PRNewswire/ -- Rogne Bioscience, a privately-held biotechnology company developing a topical biologic for psoriasis, today announced that preclinical and mechanism of action data will be presented during a poster session at the Society of Investigative Dermatology (SID) Annual Meeting being held May 6-9, 2015 at the Hilton Atlanta, in Atlanta, Georgia.
Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO
Rogne is advancing the development of RON2315, a novel, low MW (<1700 daltons) peptide as a topical treatment for psoriasis. The peptide demonstrates highly potent anti-inflammatory activity in vitro, and when applied topically to an IL-23 dependent model of dermal inflammation, RON2315 inhibits inflammation in a dose-dependent manner. Cellular and biochemical studies in human dendritic cells show that RON2315 acts by regulating the activity of NFKB-p65, thereby inhibiting the secretion of IL-23. Dendritic cells have been shown to be the primary dermal source of IL-23 driving the psoriatic disease process.
“These data highlight a novel anti-inflammatory mechanism that we believe will be a safe, topical treatment with biologic efficacy for hyper-immune diseases such as psoriasis,” said Karl Beutner, CMO. “With the demonstration that we can easily deliver the peptide into the skin and the completion of our safety/toxicology studies, our development program is progressing rapidly. We expect to have clinical proof-of-concept data in Q3 of 2015,” said Lena Wu, Ph.D. CEO.
The schedule for Rogne’s poster presentation is as follows:
Presentation Title: RON2315: A novel human biologic for the topical treatment of psoriasis
Location: Galleria Exhibit Hall
Poster number: 001
Date and Time: Poster Session I, Thursday, May 7, 2015, 10:00 am 12:00 pm
About Rogne Bioscience
Rogne Bioscience is an early stage, San Francisco Bay area-based biotechnology company focused on bringing forward novel topically administered biological treatments for inflammatory diseases. Its first clinical program will target psoriasis. For more information, please visit www.rognebioscience.com.
CONTACT: info@rognebioscience.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rogne-bioscience-to-present-data-from-topical-biologic-psoriasis-program-at-upcoming-sid-annual-meeting-2015-300076150.html
SOURCE Rogne Bioscience, Inc.
Help employers find you! Check out all the jobs and post your resume.
